lh2 051 cohorts  (MedChemExpress)

Journal: PeerJ

Article Title: UQCRC1 downregulation impairs cognitive function in mice via AMPK inactivation

doi: 10.7717/peerj.19873

Figure Lengend Snippet: (A) Schematic illustration of the experimental design for Intraperitoneal injection, created in https://BioRender.com . (B) The ATP level in UQCRC1+/- mice increased after the administration of A-769662 or LH2-051. (C) The ROS levels in UQCRC1+/- mice diminished following the treatment with A-769662 or LH2-051. (D) Representative transmission electron microscope (TEM) images (red arrows indicate lipofuscin; scale bar: 2 µm). (E) The density of lipofuscin in UQCRC1+/- mice reduced after the administration of A-769662 or LH2-051. (F) Western blot image of pAMPK, AMPK, LC3B a and LC3B II, and GAPDH. (G–J) Quantification of protein expression of LC3B II (G), pAMPK (H), AMPK (I), and pAMPK/AMPK (J). Protein levels were normalized to GAPDH as an internal loading control . (K) Following administration of A-769662 or LH2-051, activation of caspase 3 and caspase 9 in UQCRC1+/- mice was reduced. Data are represented as mean ±SEM. ∗∗∗∗ p < 0.0001, ∗∗∗ p < 0.001, ∗∗ p < 0.01, ∗ p < 0.05.

Article Snippet: Mice in the UQCRC1 +/− + A-769662 and UQCRC1 +/− + LH2-051 cohorts received intraperitoneal injections of A-769662 (30 mg/kg, MCE, CAT# HY-50662) or LH2-051 (10 mg/kg, MCE, CAT# HY-161723), administered twice daily for 30 consecutive days ( ).

Techniques: Injection, Transmission Assay, Microscopy, Western Blot, Expressing, Control, Activation Assay

Journal: PeerJ

Article Title: UQCRC1 downregulation impairs cognitive function in mice via AMPK inactivation

doi: 10.7717/peerj.19873

Figure Lengend Snippet: (A) Representative heat maps showing the duration and location of the subject during novel object recognition (“N” and “F” represent novel object and familiar object, respectively). (B) The recognition rate of UQCRC1+/- mice increased after the administration of A-769662 or LH2-051. (C) Representative figures of the nest-building test. (D) The nesting score of UQCRC1+/- mice increased after the administration of A-769662. (E) Representative trajectory chart during testing phase of the Barnes maze (gray circle indicates the target hole). (F) Over the training phase of the Barnes maze, the escape latencies of UQCRC1+/- mice were restored to levels similar to WT mice. (G) A-769662 or LH2-051 treatment lowered the escape latencies of UQCRC1+/- mice during the Barnes maze testing phase. (H) UQCRC1+/- mice treated with A-769662 or LH2-051 showed fewer attempts to find the target hole. Recognition rate in NOR and escape latencies in both the training and testing phases of the Barnes maze were quantified and expressed as mean ±SEM. Nesting score in NBT and the numbers to identify target box during Barnes maze were presented as median and interquartile range. ∗∗∗∗ p < 0.0001, ∗∗∗ p < 0.01, ∗∗ p < 0.01, ∗ p < 0.05.

Article Snippet: Mice in the UQCRC1 +/− + A-769662 and UQCRC1 +/− + LH2-051 cohorts received intraperitoneal injections of A-769662 (30 mg/kg, MCE, CAT# HY-50662) or LH2-051 (10 mg/kg, MCE, CAT# HY-161723), administered twice daily for 30 consecutive days ( ).

Techniques: